SCHEMBL2426993

SCHEMBL2426993

OC(C1CC1)C(F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10233655 1.00 PDE2A (0.31)
SCHEMBL20917640 1.00
SCHEMBL7766138 0.89 SHBG (0.39)
SCHEMBL26999233 0.88 GABBR2 (0.38)
SCHEMBL26999231 0.88 GABBR2 (0.38)
SCHEMBL28323662 0.88 GABBR2 (0.34)
SCHEMBL18987544 0.87
SCHEMBL18987545 0.87
SCHEMBL2426470 0.87
SCHEMBL7764396 0.87

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12472181-B2 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (BE) 2025-11-18 US disclosed
EP-4618974-A1 OREXIN RECEPTOR AGONISTS Merck Sharp & Dohme LLC (US) 2025-09-24 EP disclosed
US-20250145629-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. 2025-05-08 US disclosed
EP-4530288-A1 COMPOUND CONTAINING GEM-DIFLUORO GROUP, PREPARATION METHOD THEREFOR AND USE THEREOF CGeneTech (Suzhou, China) Co., Ltd. (CN) 2025-04-02 EP disclosed
EP-4511127-A1 KRAS G12D MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2025-02-26 EP disclosed
US-12145939-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators PRAXIS PRECISION MEDICINES, INC. (US) 2024-11-19 US disclosed
WO-2024107615-A1 OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2024-05-23 WO disclosed
CN-117843619-A Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and methods for preparing the modulators 弗特克斯药品有限公司 2024-04-09 CN disclosed
CN-117534670-A Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders 加拉帕戈斯股份有限公司 2024-02-09 CN disclosed
US-20240043433-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. 2024-02-08 US disclosed
US-20210171530-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. 2021-06-10 US disclosed
WO-2021108513-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. (US) 2021-06-03 WO disclosed
WO-2021108513-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. (US) 2021-06-03 WO disclosed
EP-3697784-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS Galapagos NV (BE) 2020-08-26 EP disclosed
CN-111225916-A Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders 加拉帕戈斯股份有限公司 2020-06-02 CN disclosed
WO-2019076716-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2019-04-25 WO disclosed
EP-2374802-B1 KYNURENINE PRODUCTION INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2014-04-23 EP disclosed
US-8673908-B2 Kynurenine production inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-03-18 US disclosed
EP-2374802-A1 KYNURENINE PRODUCTION INHIBITOR Kyowa Hakko Kirin Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110237584-A1 KYNURENINE PRODUCTION INHIBITOR KYOWA KIRIN CO., LTD. (JP) 2011-09-29 US disclosed